Skip to main content
SpringerLink
Log in

The China Hypertrophic Cardiomyopathy Project (CHCMP): The Rationale and Design of a Multicenter, Prospective, Registry Cohort Study

  • Methods Paper
  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Hypertrophic cardiomyopathy (HCM) is associated with adverse outcomes, such as heart failure, arrhythmia, and mortality. Sudden cardiac death (SCD) is a common cause of death in HCM patients, and identification of patients at a high risk of SCD is crucial in clinical practice. The China Hypertrophic Cardiomyopathy Project is a hospital-based, multicenter, prospective, registry cohort study of HCM patients, covering a total of 3000 participants and with a 5-year follow-up plan. A large number of demographic characteristics and clinical data will be fully collected to identify prognostic factors in Chinese HCM patients. Furthermore, the main purpose of this study is to integrate demographic and clinical characteristics to establish new 5-year SCD risk predictive equations for Chinese HCM patients by the use of machine learning technologies. The project has crucial clinical significance for risk stratification and determination of HCM patients with high risk of adverse outcomes.

Clinical trials registration

ChiCTR2300070909

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tuohy CV, et al. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22(2):228–40.

    Article  PubMed  Google Scholar 

  2. Ommen SR, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558–631.

    PubMed  Google Scholar 

  3. Liu J, et al. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020;17(10):1658–63.

    Article  PubMed  Google Scholar 

  4. Semsarian C, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54.

    Article  PubMed  Google Scholar 

  5. Norrish G, et al. Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79(20):1986–97.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655–68.

    Article  PubMed  Google Scholar 

  7. Authors/Task Force, m., et al., 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J, 2014. 35(39): p. 2733-79.

  8. Maron MS, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4(7):644–57.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dong Y, et al. Validation of the 2020 AHA/ACC risk stratification for sudden cardiac death in Chinese patients with hypertrophic cardiomyopathy. Front Cardiovasc Med. 2021;8: 691653.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wang, J., et al., Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines. Eur Heart J, 2023.

  11. Leonardi S, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30(16):2003–10.

    Article  PubMed  Google Scholar 

  12. Hen Y, et al. High signal intensity on t2-weighted cardiovascular magnetic resonance imaging predicts life-threatening arrhythmic events in hypertrophic cardiomyopathy patients. Circ J. 2018;82(4):1062–9.

    Article  PubMed  Google Scholar 

  13. Ismail TF, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart. 2014;100(23):1851–8.

    Article  PubMed  Google Scholar 

  14. Ochoa JP, et al. Formin Homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;72(20):2457–67.

    Article  CAS  PubMed  Google Scholar 

  15. Lopes LR, et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. Eur Heart J. 2021;42(32):3063–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Matthia EL, et al. Circulating biomarkers in hypertrophic cardiomyopathy. J Am Heart Assoc. 2022;11(23):e027618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Johnson KW, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668–79.

    Article  PubMed  Google Scholar 

  18. Motwani M, et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. Eur Heart J. 2017;38(7):500–7.

    PubMed  Google Scholar 

  19. Deo RC. Machine learning in medicine. Circulation. 2015;132(20):1920–30.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Weng SF, et al. Can machine-learning improve cardiovascular risk prediction using routine clinical data? PLoS One. 2017;12(4):e0174944.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Heo J, et al. Machine learning-based model for prediction of outcomes in acute stroke. Stroke. 2019;50(5):1263–5.

    Article  PubMed  Google Scholar 

  22. Alaa AM, et al. Cardiovascular disease risk prediction using automated machine learning: a prospective study of 423,604 UK Biobank participants. PLoS One. 2019;14(5):e0213653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Al’Aref SJ, et al. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. Eur Heart J. 2019;40(24):1975–86.

    Article  CAS  PubMed  Google Scholar 

  24. Javaid A, et al. Medicine 2032: The future of cardiovascular disease prevention with machine learning and digital health technology. Am J Prev Cardiol. 2022;12:100379.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lang RM, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39 (e14).

    Article  PubMed  Google Scholar 

  26. Sasson Z, et al. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;11(4):752–6.

    Article  CAS  PubMed  Google Scholar 

  27. Kumar S, et al. Standardized goal-directed valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2018;31(7):791–8.

    Article  PubMed  Google Scholar 

  28. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389(10075):1253–67.

    Article  PubMed  Google Scholar 

  29. Porter TR, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2014;27(8):797–810.

    Article  PubMed  Google Scholar 

  30. Kramer CM, et al. Hypertrophic cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015;170(2):223–30.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ingles, J. and D.G. MacArthur, The moral and practical urgency of increasing diversity in genomics. Eur Heart J, 2023.

  32. Ingles J, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12(2):e002460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang J, et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail. 2014;16(9):950–7.

    Article  PubMed  Google Scholar 

  34. Pua CJ, et al. Genetic studies of hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2 that are common in chinese patients. Circ Genom Precis Med. 2020;13(5):424–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Walsh R, et al. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol. 2022;19(3):151–67.

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by grants from the National Natural Science Foundation of China (82170331), Joint Funds from the National Natural Science Foundation of China (U21A20337), and grants from the Key Research and Development Plan of Zhejiang Province (2020C03017).

Author information

Authors and Affiliations

  1. Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    Zhi Du, Kai Wang, Yawei Cui, Xudong Xie, Ruoyu Zhu, Fanghong Dong & Xiaogang Guo

Authors
  1. Zhi Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yawei Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xudong Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ruoyu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fanghong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaogang Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

X.G. was responsible for the concept and design of the study. Z.D. contributed to the drafting of the article. K.W., Y.C., X.X., R.Z., and F.D. reviewed and edited the draft. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xiaogang Guo.

Ethics declarations

Ethics Approval and Consent to Participate

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). This protocol was approved by the Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine (No. IIT220434B-R2). Informed consent was obtained from all patients for being included in the study.

Competing interests

The authors declare no competing interests.

Patient and Public Involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Additional information

Associate Editor Paul J. R. Barton oversaw the review of this article.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 59 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, Z., Wang, K., Cui, Y. et al. The China Hypertrophic Cardiomyopathy Project (CHCMP): The Rationale and Design of a Multicenter, Prospective, Registry Cohort Study. J. of Cardiovasc. Trans. Res. (2024). https://doi.org/10.1007/s12265-023-10477-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12265-023-10477-4

Keywords

Search

Navigation